Science Corporation Reaches $3.5 Billion Valuation on Vision-Restoration Push
Max Hodak's medical-device venture secured $400 million in Series D backing as it prepares US trials for a retinal implant and designs a bio-hybrid brain sensor with Yale researchers.
A Medical-Device Bet at Neurotech Scale
Science Corporation, the medical-technology venture led by Max Hodak, closed a $400 million Series D financing that values the business at $3.5 billion. The round drew participation from Khosla Ventures, the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator and PLC Neurotech.
Hodak, who left his role as president of Neuralink in 2021 and launched Science Corporation the same year, has spent the intervening period building a portfolio of neural-interface technologies. His background traces to an undergraduate stint in which he persuaded a graduate neuroscience laboratory to admit him, setting in motion a career focused on biotechnology and brain-machine systems.
The valuation - more than three times the company's Series C figure - reflects investor confidence in a commercial product already generating revenue in Europe and a research pipeline that extends to direct brain interfaces. It also underscores the momentum in the neurotech sector, where venture capital has flowed toward teams with both regulatory experience and a path to near-term commercialisation rather than purely speculative brain-computer interfaces.
PRIMA: A Retinal Implant in Clinical Use
Science Corporation's lead product is PRIMA, a system that combines a wearable projector with an implantable chip designed to restore partial vision in people with age-related macular degeneration. The device has secured regulatory approval in Europe and is available to patients in Germany.
Age-related macular degeneration damages the central portion of the retina, leaving peripheral vision intact but eroding the ability to read, recognise faces or perform tasks that require fine detail. PRIMA bypasses the damaged photoreceptors by projecting images onto a subretinal chip, which converts light into electrical pulses that stimulate the remaining retinal cells. The approach does not restore normal vision but can return enough functional sight to improve daily independence.
Hodak announced at TechCrunch Disrupt that the company is now enrolling patients with Stargardt disease, a genetic condition that causes early-onset macular degeneration, in a new trial. Stargardt typically manifests in childhood or adolescence, and its inclusion in Science Corporation's clinical programme signals an effort to broaden the addressable patient population beyond the elderly.
The company is preparing to bring PRIMA to the United States through the Food and Drug Administration's Humanitarian Device Exemption pathway, which permits the use of experimental medical devices for conditions affecting fewer than 8,000 people per year. Science Corporation has persuaded the FDA that advanced macular degeneration affecting both eyes meets this threshold, a regulatory classification that accelerates approval but limits the scale of initial deployment.
The Humanitarian Device Exemption as a Bridgehead
The Humanitarian Device Exemption represents a calculated regulatory strategy. By framing advanced bilateral macular degeneration as a rare condition, Science Corporation can enter the US market without the multi-year pivotal trials required for a standard pre-market approval. The trade-off is volume: devices approved under this pathway cannot be sold for profit, and manufacturers must demonstrate that revenue covers only costs.
For Science Corporation, the exemption offers a foothold in the US healthcare system and a platform for gathering real-world data that can support future label expansions. If PRIMA proves effective in the initial cohort, the company can pursue broader indications - such as earlier-stage macular degeneration or other retinal diseases - through supplemental filings that leverage the existing safety record.
The European approval, meanwhile, provides a revenue stream and a proving ground for device iterations. Germany's healthcare system reimburses the procedure, and the company has been refining surgical techniques and patient-selection criteria in collaboration with ophthalmology centres there. That operational experience will be critical when Science Corporation scales US distribution, where reimbursement negotiations with Medicare and private insurers will determine commercial viability.
Bio-Hybrid Sensors and the Brain-Interface Ambition
Beyond retinal implants, Science Corporation is developing a bio-hybrid sensor that combines cultured neurons with silicon electronics. The device is intended to interface directly with brain tissue, a step beyond current electrode arrays that record or stimulate neural activity without integrating biological components.
The company is designing initial human trials in partnership with Murat Günel, a professor of neurosurgery at Yale University. Günel has indicated that the sensor could be tested for Parkinson's disease, a neurodegenerative disorder characterised by motor dysfunction, as well as other brain injuries and neurological conditions.
Parkinson's affects approximately 10 million people worldwide, and current treatments - primarily dopamine-replacement drugs and deep-brain stimulation - manage symptoms but do not halt disease progression. A bio-hybrid interface could, in theory, offer more precise modulation of neural circuits by integrating living cells that adapt to the surrounding tissue, reducing the immune response and improving signal fidelity over time.
The technical challenges are formidable. Cultured neurons must survive implantation, form stable connections with host tissue, and interface reliably with the silicon components that transmit data to external processors. Science Corporation has not disclosed the design details, but the approach likely involves microfluidic channels to nourish the cells, biocompatible scaffolds to guide neurite growth, and multiplexed electrodes to record from individual neurons or small ensembles.
Neurotech's Shift Toward Clinical Products
The $3.5 billion valuation places Science Corporation among the most highly valued private neurotech companies, a category that includes Synchron, Paradromics and Precision Neuroscience alongside the better-known Neuralink. What distinguishes Science Corporation is its dual focus: a commercial device already in clinical use and a research-stage brain interface that remains years from human deployment.
This structure appeals to investors who want exposure to neurotech's long-term potential without relying entirely on unproven technology. PRIMA generates revenue, validates the team's ability to navigate regulatory systems in multiple jurisdictions, and demonstrates demand for neural interfaces that address unmet medical needs. The bio-hybrid sensor, meanwhile, offers upside if the technology succeeds but does not determine the company's near-term survival.
The investor roster reflects this balance. Khosla Ventures has a history of backing ambitious biotech and hardware companies with long development timelines. Tenet Healthcare, a hospital operator, brings strategic insight into care delivery and reimbursement. Y Combinator's participation signals confidence in the team's execution, while PLC Neurotech - a fund focused on neural-interface technologies - adds domain expertise.
Regulatory and Reimbursement Hurdles Ahead
Science Corporation's path to scale depends on clearing two distinct hurdles: regulatory approval for new indications and reimbursement agreements that make the devices economically accessible. The Humanitarian Device Exemption solves the first problem for a narrow patient group, but broader adoption will require data showing that PRIMA improves quality of life enough to justify the cost of surgery, device maintenance and follow-up care.
In Europe, the company has benefited from centralised approval through the CE mark and national reimbursement decisions that treat the device as a covered procedure. The US market is more fragmented. Medicare sets payment rates for the elderly, the primary demographic for age-related macular degeneration, but private insurers negotiate separately, and coverage policies vary by region and plan.
The Stargardt trial complicates the reimbursement picture. Younger patients with genetic retinal disease represent a smaller market, but they also face decades of vision loss, making the lifetime value of a successful intervention much higher. If Science Corporation can demonstrate durable benefit in this cohort, it strengthens the economic case for early intervention across retinal diseases.
What the Funding Enables
The $400 million Series D will fund US clinical trials, expand manufacturing capacity for PRIMA, and advance the bio-hybrid sensor toward human testing. The company has not disclosed a timeline for the Yale trials, but first-in-human studies for invasive brain devices typically require at least two years of preclinical work, including safety testing in animal models and design validation.
Manufacturing scale is a near-term priority. PRIMA's subretinal chip is fabricated using semiconductor processes, but the wearable projector and surgical tools require custom engineering. As the company moves from European centres of excellence to a broader US rollout, it will need to train surgeons, establish supply chains for sterile components, and build service networks for device maintenance.
The financing also positions Science Corporation to pursue acquisitions or partnerships that fill gaps in its technology stack. Neural interfaces depend on advances in materials science, wireless power transfer, data compression and biocompatible coatings - domains where smaller startups and research labs hold valuable intellectual property.
A Neuroscience Founder's Second Act
Hodak's departure from Neuralink in 2021 was amicable, but it marked a strategic divergence. Neuralink has focused on high-bandwidth brain-computer interfaces for paralysis and, eventually, cognitive enhancement. Science Corporation has pursued a more incremental path, starting with a sensory prosthetic that addresses a well-defined clinical need and building toward more invasive brain interfaces only after proving the team's regulatory and commercial capabilities.
That approach has attracted capital at a pace that rivals Neuralink's own fundraising. The $3.5 billion valuation, while still private and subject to the usual caveats about late-stage venture pricing, suggests that investors see a viable business model in neurotech beyond the moonshot ambitions that dominate headlines.
The next eighteen months will test whether that confidence is justified. US trials for PRIMA will generate the safety and efficacy data needed for broader approval. The Stargardt programme will show whether the device works in younger patients with different disease mechanisms. And the bio-hybrid sensor will move from concept to prototype, revealing whether Science Corporation can deliver on the founding vision that brought Hodak into neuroscience in the first place.



